AUG 21, 2014 12:00 AM PDT

New Life Sciences Research Reveals Early Stage Treatments to Help Scientists in the Fight against Ebola

The Intellectual Property and Science business of Thomson Reuters released a comprehensive disease profile on Ebola Virus Disease that includes a detailed analysis of two new treatments in the pipeline and two experimental candidates approaching development. The disease profile is designed to provide greater understanding of key Ebola treatments in the drug pipeline and experimental therapies approaching development.

Ebola deaths in West Africa have exceeded the 1,000 mark since ravaging Liberia. Practitioners in Britain were recently ordered to look out for symptoms of the killer virus to stop it from taking hold in the UK, with doctors receiving new guidelines on how to deal with suspected cases. Ebola Virus Disease is particularly lethal. According to the World Health Organization, outbreaks have a fatality rate of up to 90 percent. There is currently no effective treatment.

The Thomson Reuters Ebola Disease Briefing is available free of charge through its LS Research website, a resource providing researchers with the latest news on disease insights and developing treatments, through reports and biological pathway maps. This resource offers disease profiling and comparative data to the current drug landscape for clinically devastating, relevant diseases, such as Ebola.

"Our LS Research resource is designed to place valuable scientific insights into the hands of researchers to offer new angles on understanding devastating diseases - not just as related to Ebola, but for other conditions that continue to compromise quality of life for people around the world," said Jon Brett-Harris, managing director of Thomson Reuters Life Sciences.

Through analysis using Thomson Reuters Integrity - a resource providing researchers with detailed drug R&D information across multiple disciplines - LS Research analysts identified two potential Ebola treatments in the drug pipeline: Sarepta Therapeutics' VP24 expression inhibitor known as "AVI-7537" and Tekmira's VP24 expression inhibitor known as "Ebola SNALP."

VP24 is believed to play a significant role in Ebola Virus Disease, and may have an effect on the formation and replication of the viral genome. Scientists are now exploring the inhibition of this VP24 protein as a potential treatment to block the building and reproduction of the Ebola Virus genome. Both of these treatments are currently in Phase 1 clinical trials. The LS Research site also provides comprehensive information on the disease itself.

There are also two experimental treatment approaches set to move into the pipeline. The first, ZMapp, a novel drug candidate in development by Mapp BioPharmaceutical, LeafBio, Defyru, the U.S. Government and the Public Health Agency of Canada (PHAC), is a cocktail of three different humanized monoclonal antibodies produced in nicotina plants that target the virus. The aim of this potential therapy is to halt the progression of Ebola; it was recently successful in treating two American healthcare workers infected by the outbreak in West Africa. The second is a vaccine candidate, rVSVdeltaG-SWGP-2A-MFL, being developed by the Beijing Institute of Biotechnology. It consists of a recombinant vesicular stomatitis virus expressing multiple regional fragments of the Ebola virus.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 14, 2018
Microbiology
JUL 14, 2018
Little-known STI may Become a Superbug
Scientists are growing concerned about a common sexually transmitted infection that not many people know about - MG or MGen....
SEP 09, 2018
Videos
SEP 09, 2018
Black Hairy Tongue - A Shocking Antibiotic Side Effect
A 55-year-old woman experienced a rare side effect of antibiotics while being treated for an infection....
SEP 10, 2018
Microbiology
SEP 10, 2018
As Microbes Jump From Animals to Humans, Their Genes Change
We share the world with an untold number of microorganisms, most of which pose no threat to us; but some microbes can be very dangerous if they infect us....
SEP 15, 2018
Microbiology
SEP 15, 2018
Researchers Surprised to Find Bacteria That Make Electricity in the Human Gut
It seems that many microbes, including strains in the human gut that are potentially pathogenic, can generate electricity....
SEP 22, 2018
Videos
SEP 22, 2018
Did a Vampire Facial Expose Patients to Bloodborne Disease?
It seems there is no shortage of unusual beauty rituals; vampire facials may fall into that category....
SEP 25, 2018
Videos
SEP 25, 2018
Post-Hurricane Bacterial Threats
Natural disasters like hurricanes are dangerous when they occur, and their aftermath poses another set of problems....
Loading Comments...